Adjunctive ketamine vs. buprenorphine in co-occurring major depressive disorder and opioid use disorder: a randomized, double-blind clinical trial assessing anxiety symptom severity and craving intensity

Authors

Institutions

Publication Details

Journal
Trials
Published
2025-04-17
DOI
https://doi.org/10.1186/s13063-025-08836-4
Citations
4
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
5.58
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Adjunctive ketamine vs. buprenorphine in co-occurring major depressive disorder and opioid use disorder: a randomized, double-blind clinical trial assessing anxiety symptom severity and craving intensity

Amir Bazrafshan, Jamshid Ahmadi, Seyed Hamdollah Mosavat, Arash Mansoori
4 citations
Trials
Treatment of Major Depression
5.58
article

Adjunctive ketamine vs. buprenorphine in co-occurring major depressive disorder and opioid use disorder: a randomized, double-blind clinical trial assessing anxiety symptom severity and craving intensity

Amir Bazrafshan, Jamshid Ahmadi, Seyed Hamdollah Mosavat, Arash Mansoori
article en
4 citations

Abstract

No abstract available for this paper.
TrialsVol. 26(1)
Shiraz University of Medical Sciences (IR), Community Counseling Services (US)
Openalex Percentile: Top 4%
Treatment of Major Depression
5.58
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.